Your browser doesn't support javascript.
loading
Mutational fitness landscapes reveal genetic and structural improvement pathways for a vaccine-elicited HIV-1 broadly neutralizing antibody.
Madan, Bharat; Zhang, Baoshan; Xu, Kai; Chao, Cara W; O'Dell, Sijy; Wolfe, Jacy R; Chuang, Gwo-Yu; Fahad, Ahmed S; Geng, Hui; Kong, Rui; Louder, Mark K; Nguyen, Thuy Duong; Rawi, Reda; Schön, Arne; Sheng, Zizhang; Nimrania, Rajani; Wang, Yiran; Zhou, Tongqing; Lin, Bob C; Doria-Rose, Nicole A; Shapiro, Lawrence; Kwong, Peter D; DeKosky, Brandon J.
Afiliação
  • Madan B; Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66045.
  • Zhang B; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
  • Xu K; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
  • Chao CW; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
  • O'Dell S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
  • Wolfe JR; Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66045.
  • Chuang GY; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
  • Fahad AS; Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66045.
  • Geng H; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
  • Kong R; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
  • Louder MK; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
  • Nguyen TD; Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66045.
  • Rawi R; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
  • Schön A; Department of Biology, John Hopkins University, Baltimore, MD 21218.
  • Sheng Z; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10027.
  • Nimrania R; Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66045.
  • Wang Y; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
  • Zhou T; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
  • Lin BC; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
  • Doria-Rose NA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
  • Shapiro L; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
  • Kwong PD; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10027.
  • DeKosky BJ; Aaron Diamond AIDS Research Center, Columbia University Irving Medical Center, New York, NY 10032.
Proc Natl Acad Sci U S A ; 118(10)2021 03 09.
Article em En | MEDLINE | ID: mdl-33649208
Vaccine-based elicitation of broadly neutralizing antibodies holds great promise for preventing HIV-1 transmission. However, the key biophysical markers of improved antibody recognition remain uncertain in the diverse landscape of potential antibody mutation pathways, and a more complete understanding of anti-HIV-1 fusion peptide (FP) antibody development will accelerate rational vaccine designs. Here we survey the mutational landscape of the vaccine-elicited anti-FP antibody, vFP16.02, to determine the genetic, structural, and functional features associated with antibody improvement or fitness. Using site-saturation mutagenesis and yeast display functional screening, we found that 1% of possible single mutations improved HIV-1 envelope trimer (Env) affinity, but generally comprised rare somatic hypermutations that may not arise frequently in vivo. We observed that many single mutations in the vFP16.02 Fab could enhance affinity >1,000-fold against soluble FP, although affinity improvements against the HIV-1 trimer were more measured and rare. The most potent variants enhanced affinity to both soluble FP and Env, had mutations concentrated in antibody framework regions, and achieved up to 37% neutralization breadth compared to 28% neutralization of the template antibody. Altered heavy- and light-chain interface angles and conformational dynamics, as well as reduced Fab thermal stability, were associated with improved HIV-1 neutralization breadth and potency. We also observed parallel sets of mutations that enhanced viral neutralization through similar structural mechanisms. These data provide a quantitative understanding of the mutational landscape for vaccine-elicited FP-directed broadly neutralizing antibody and demonstrate that numerous antigen-distal framework mutations can improve antibody function by enhancing affinity simultaneously toward HIV-1 Env and FP.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / HIV-1 / Vacinas contra a AIDS / Produtos do Gene env do Vírus da Imunodeficiência Humana / Anticorpos Amplamente Neutralizantes / Mutação Limite: Humans Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / HIV-1 / Vacinas contra a AIDS / Produtos do Gene env do Vírus da Imunodeficiência Humana / Anticorpos Amplamente Neutralizantes / Mutação Limite: Humans Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2021 Tipo de documento: Article